公开(公告)号：US10266532B2

公开(公告)日：2019-04-23

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson ,  Jerome Daanen ,  Stevan Djuric ,  Amanda W. Dombrowski ,  Arthur Gomtsyan ,  Robert Schmidt

IPC: C07D521/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20180179198A1

公开(公告)日：2018-06-28

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson

IPC: C07D471/04 ,  C07D491/147 ,  C07D498/22 ,  C07D487/04 ,  C07D491/22 ,  C07D498/18 ,  C07D471/14 ,  C07D498/04 ,  C07D498/14 ,  C07D498/20 ,  C07D519/00 ,  C07D471/18

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20170320880A1

公开(公告)日：2017-11-09

申请号：US15588398

申请日：2017-05-05

Applicant: AbbVie Inc.

Inventor： Michael R. Michaelides ,  Michael L. Curtin ,  Huan-Qiu Li ,  Marina A. Pliushchev ,  Ying Wang ,  Hongyu H. Zhao ,  Richard F. Clark ,  Alan S. Florjancic ,  Zhiqin Ji ,  Mariazel Torrent ,  Ramzi F. Sweis ,  Anil Vasudevan ,  Justin D. Dietrich

IPC: C07D487/04 ,  C07D417/14 ,  C07D413/10 ,  C07D405/04 ,  C07D403/14 ,  C07D403/12 ,  C07D403/10 ,  C07D403/04 ,  C07D401/14 ,  C07D401/12 ,  C07D401/04 ,  C07D471/04 ,  C07D207/14

CPC classification number: C07D487/04 ,  A61K31/40 ,  C07D207/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D413/10 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US20170174624A1

公开(公告)日：2017-06-22

申请号：US15398978

申请日：2017-01-05

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux ,  Heather M. Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep K. Somal ,  Jennifer Van Camp ,  Stacy A. Van Epps ,  Anil Vasudevan ,  Grier A. Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D209/08 ,  C07D405/14 ,  C07D403/04 ,  C07D401/04 ,  C07D209/18 ,  C07D405/04 ,  C07D209/12 ,  C07D209/10 ,  C07D209/14 ,  C07D417/14 ,  C07D401/14 ,  C07D409/14 ,  C07D403/10 ,  C07D409/04 ,  C07D409/12 ,  C07D403/14 ,  C07D413/04

CPC classification number: C07D209/08 ,  A61P35/00 ,  C07D209/10 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US09656955B2

公开(公告)日：2017-05-23

申请号：US14216222

申请日：2014-03-17

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Wilhelm Amberg ,  Frauke Pohlki ,  Udo Lange ,  Ying X. Wang ,  Hongyu H. Zhao ,  Huan-Qiu Li ,  Jason T. Brewer ,  Irini Zanze ,  Justin Dietrich ,  Anil Vasudevan ,  Stevan W. Djuric ,  Yanbin Lao ,  Charles W. Hutchins

IPC: A61K31/4025 ,  A61K31/44 ,  A61K31/4178 ,  C07D207/09 ,  C07D403/12 ,  C07D401/12 ,  C07D207/48 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D487/10 ,  C07D417/14 ,  C07D409/14 ,  C07D495/04 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D207/48 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

公开(公告)号：US20150322045A1

公开(公告)日：2015-11-12

申请号：US14410952

申请日：2013-06-28

Applicant: Abbvie Inc.

Inventor： Artour Gomtsian ,  Tatyana Dekhtyar ,  Kristine E. Frank ,  Michael M. Friedman ,  Nathan Josephsohn ,  M-Akhteruzz Molla ,  Anil Vasudevan ,  Teresa Ng ,  Mikhail Chafeev

IPC: C07D403/04 ,  A61K31/498 ,  C07D413/04 ,  A61K31/496 ,  C07D417/04 ,  A61K31/517 ,  C07D487/04 ,  A61K31/519 ,  C07D405/14 ,  C07D403/14 ,  A61K31/499 ,  A61K31/5377 ,  C07D471/04 ,  A61K31/4985 ,  C07D401/14 ,  A61K31/497

CPC classification number: C07D241/26 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  C07C335/30 ,  C07D231/40 ,  C07D241/44 ,  C07D317/66 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本公开涉及：（a）其特别是抑制RSV感染和/或复制的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US20150005279A1

公开(公告)日：2015-01-01

申请号：US14315504

申请日：2014-06-26

Applicant: ABBVIE INC.

Inventor： Dominique Bonafoux ,  Heather M. Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep K. Somal ,  Jennifer Van Camp ,  Stacy A. Van Epps ,  Anil Vasudevan ,  Grier A. Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D487/04 ,  C07D471/04 ,  C07D209/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D231/56 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D209/08 ,  C07D209/10 ,  C07D209/12 ,  C07D209/14 ,  C07D209/18 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 本发明提供式（I）化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：US20140275087A1

公开(公告)日：2014-09-18

申请号：US14216222

申请日：2014-03-17

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Wilhelm Amberg ,  Frauke Pohlki ,  Udo Lange ,  Ying X. Wang ,  Hongyu H. Zhao ,  Huan-Qiu Li ,  Jason T. Brewer ,  Irini Zanze ,  Justin Dietrich ,  Anil Vasudevan ,  Stevan W. Djuric ,  Yanbin Lao ,  Charles W. Hutchins

IPC: C07D207/48 ,  C07D403/14 ,  C07D401/14 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D207/48 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.

Abstract translation: 本发明涉及式（I）的吡咯烷衍生物或其生理上耐受的盐。 本发明涉及包含这种吡咯烷衍生物的药物组合物以及这种吡咯烷衍生物用于治疗目的的用途。 吡咯烷衍生物是GlyT1抑制剂。

公开(公告)号：US20190290632A1

公开(公告)日：2019-09-26

申请号：US16276144

申请日：2019-02-14

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Wilhelm Amberg ,  Frauke Pohlki ,  Udo Lange ,  Ying Wang ,  Jason Brewer ,  Anil Vasudevan ,  Yanbin Lao ,  Charles Hutchins ,  Hongyu Zhao ,  Huan-Qiu Li

IPC: A61K31/454 ,  C07D405/14 ,  C07D403/10 ,  A61K31/4192 ,  A61K31/4178 ,  A61K31/4025 ,  C07D403/12 ,  C07D403/14 ,  C07D207/273 ,  C07D205/04 ,  C07D401/12 ,  C07D233/42 ,  A61K31/397

Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.

公开(公告)号：US10093624B2

公开(公告)日：2018-10-09

申请号：US14880834

申请日：2015-10-12

Applicant: AbbVie Inc.

Inventor： Rick F. Clark ,  Michael L. Curtain ,  Todd M. Hansen ,  Howard R. Heyman ,  Helmut Mack ,  Michael Michaelides ,  Marina A. Pliushchev ,  Omar J. Shah ,  Bryan K. Sorensen ,  Ramzi Sweis ,  Chris Tse ,  Anil Vasudevan ,  Kevin R. Woller

IPC: A01N43/42 ,  A61K31/44 ,  C07D209/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D407/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  A61K31/437 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D519/00

Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.